Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial

Abstract

Our previous studies have shown that mangiferin decreased serum triglycerides and free fatty acids (FFAs) by increasing FFAs oxidation in both animal and cell experiments. This study sought to evaluate the effects of mangiferin on serum lipid profiles in overweight patients with hyperlipidemia. Overweight patients with hyperlipidemia (serum triglyceride ≥ 1.70 mmol/L, and total cholesterol ≥ 5.2 mmol/L) were included in this double-blind randomized controlled trial. Participants were randomly allocated to groups, either receiving mangiferin (150 mg/day) or identical placebo for 12 weeks. The lipid profile and serum levels of mangiferin, glucose, L-carnitine, β-hydroxybutyrate, and acetoacetate were determined at baseline and 12 weeks. A total of 97 participants completed the trial. Compared with the placebo control, mangiferin supplementation significantly decreased the serum levels of triglycerides and FFAs, and insulin resistance index. Mangiferin supplementation also significantly increased the serum levels of mangiferin, high-density lipoprotein cholesterol, L-carnitine, β-hydroxybutyrate, and acetoacetate, and increased lipoprotein lipase activity. However, there were no differences in the serum levels of total cholesterol, low-density lipoprotein cholesterol, serum glucose, and insulin between groups. Mangiferin supplementation could improve serum lipid profiles by reducing serum triglycerides and FFAs in overweight patients with hyperlipidemia, partly due to the promotion of FFAs oxidation.

Consumption of a Mango Fruit Powder Protects Mice from High-Fat Induced Insulin Resistance and Hepatic Fat Accumulation

“…It has been reported that MGF may ameliorate high-fat diet-induced hepatic TG accumulation and may decrease FFA and TG while increasing plasma beta-hydroxybutyrate levels in rodents [37-39], partly by modulating the expression of genes involved in lipid oxidation and mitochondrial bioenergetics in key metabolic tissues [37-40]. In a randomized, double-blind, controlled trial in humans, MGF supplementation (150 mg/day 12 weeks) improved serum lipid profiles in overweight patients with hyperlipidemia [17]. Moreover, it has been also reported that mangiferin significantly increases FFA uptake and significantly decreases TG accumulation by activation of AMPK and its downstream proteins, fatty acid translocase CD36 and Cpt1a, both involved in lipid catabolism, in HepG2 cells [39].…”

“…It has been reported that MGF may protect against hyperglycemia, hyperinsulinemia, and insulin resistance in high-fat diet-fed mice [51], in diabetic insulin-resistant rats [37], and in overweight patients [17], as well as against accelerated glucose uptake and utilization in cultured adipocytes and myotubes [51, 52]. However, MGF did not significantly affect fatty acid oxidation even under a high-fat dietary challenge [51].…”

“…is a globally consumed fruit with reported health-promoting properties [10-13] and, based on studies in rats [14, 15] and humans [16, 17], its habitual consumption may contribute to the prevention of diabetes mellitus, obesity, and related complications. In addition, it has been reported that the food ingredient Careless TM , a 100% pure mango fruit powder characterized by a high content in secondary plant metabolites, including gallic acid, rutin and mangiferin (MGF) [18], activates sirtuin 1 (SIRT1) and AMP-activated protein kinase (AMPK) in cell systems [19], which are both involved in energy homeostasis and glucose and lipid metabolism.…”

Mitigation of Insulin Resistance by Mangiferin in a Rat Model of Fructose-Induced Metabolic Syndrome Is Associated with Modulation of CD36 Redistribution in the Skeletal Muscle

“…However, the underlying mechanisms of action are still largely unknown. We and others have reported that they improve numerous lipid metabolism-associated abnormalities, such as fatty liver, hyperlipidemia, excessive cardiac lipid accumulation and obesity (Huang et al, 2006a,b;Guo et al, 2011;Niu et al, 2012;Liu et al, 2013;Xing et al, 2014;Na et al, 2015). We hypothesized that regulation of lipid metabolism might be associated with the antidiabetic property of mangiferin.…”

“…Mangiferin and the related herbs have been demonstrated to have antidiabetic activity in rodents (Ichiki et al, 1998;Li et al, 2004;Li et al, 2008;Muruganandan et al, 2005;Akase et al, 2011;Apontes et al, 2014;Han et al, 2015). Furthermore, it has been recently reported that mangiferin supplementation improves insulin resistance index in overweight patients (Na et al, 2015). However, the underlying mechanisms of action are still largely unknown.…”